RWRyan Wang

Ryan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ryan Wang has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Spinal solitary fibrous tumor metastatic to the fourth ventricle: illustrative case

    by Ryan Wang, Shervin Pejhan, Claire I. Coire, Lee Cyn Ang, Joseph F. Megyesi

    BACKGROUND: CNS solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms that arise from the meninges and are characterized by a NAB2-STAT6 gene fusion and abundant STAT6 nuclear expression on immunohistochemistry. On imaging, SFTs can mimic meningiomas, but they differ in their clinical behavior. CNS SFTs have a propensity to recur locally and metastases, although rare, have been described. OBSERVATIONS: The authors report the case of a 76-year-old male with a history of a lower cervical spine SFT treated with surgery and radiation therapy. He presented with progressively worsening gait and balance, and headaches. Imaging showed a fourth ventricular mass that was resected via a midline suboccipital craniectomy. Pathological analysis showed a WHO grade 2 epithelioid SFT, confirmed by STAT6 expression and a rare NAB2ex5-STAT6ex17 fusion variant. The histology slides from 22 years prior were compared and found to be similar, suggesting metastasis of the original tumor. LESSONS: To the authors’ knowledge, this is the first reported case of a spinal SFT with metastasis to the fourth ventricle and the first epithelioid SFT presenting within the fourth ventricle. Long-term follow-up is recommended due to the risk of local recurrence and metastases. https://thejns.org/doi/10.3171/CASE25414

  • Hybrid Treatment Approach for a Rare Middle Cranial Fossa Intracranial Tumor in a Pediatric Patient: A Case Report

    by Ryan Wang, Shervin Pejhan, Qi Mbbs Zhang, Robert Siddaway, Cynthia Hawkins, S. Danielle MD MacNeil, Glenn Bauman, Sandrine de Ribaupierre, Chantel Cacciotti

    Pediatric central nervous system (CNS) tumors are often classified by distinct histologic and molecular features; however, some tumors remain unclassified, resulting in diagnostic and therapeutic challenges. We report a case of a previously healthy 3-year-old female who presented with right eyelid ptosis and headache. Imaging revealed a right middle cranial fossa mass. Following surgery and histopathologic and molecular analyses, the diagnosis was a malignant neoplasm with mixed neural and myoblastic differentiation, not elsewhere classified based on the current World Health Organization (WHO) classification. We describe a unique hybrid treatment approach for this rare tumor consisting of rhabdomyosarcoma and embryonal treatment regimens.

  • Evolution of the Neurosurgeon's Role in Clinical Trials for Glioblastoma: A Systematic Overview of the Clinicaltrials.Gov Database

    by Alireza Mansouri, Michelle E Beyn, Aditya Pancholi, Clement T Chow, Ryan Wang, Alexandre Boutet, Gavin J B Elias, Jurgen Germann, Aaron Loh, Mathew R Voisin, et al.

    BACKGROUND: The therapeutic challenge of glioblastoma (GBM) has catalyzed the development of clinical trials to evaluate novel interventions. With increased understanding of GBM biology and technological advances, the neurosurgeon's role in neuro-oncology has evolved. OBJECTIVE: To evaluate the current landscape of procedure-based clinical trials for GBM to characterize this evolution, gain insight into past failures, and accordingly outline implications for future research and practice that may inform future studies. METHODS: The ClinicalTrials.gov database was searched for surgical/procedural trials in individuals with GBM. Demographics, specific intervention, trial phase, and main outcome measures were abstracted. RESULTS: A total of 224 of 2311 GBM trials (9.7%) were identified as procedural, with the majority being based in the United States (155/224, 69.2%), single-center (155/224, 69.2%), and not randomized (176/224, 78.6%). Primary and recurrent GBMs were evenly addressed. The leading interventions were local delivery of therapeutics (50.0%), surgical techniques (33.9%), such as image-guided surgery, and novel device applications (14.3%). Phase I designs predominated (82/224, 36.6%). The top primary outcome was safety/tolerability/feasibility (88/224, 39.3%), followed by survival (46/224, 20.5%). Approximately 17% of studies were terminated, withdrawn, or suspended. Fifty-two linked publications were identified, among which 42 were classified as having a positive result. CONCLUSION: Procedural interventions comprised ∼10% of all registered GBM trials. Local delivery of therapeutics, use of surgical imaging techniques and novel device applications, predominantly through phase I designs, represent the evolved role of the neurosurgeon in neuro-oncology. Improved reporting of trial designs, outcomes, and results are needed to better inform the field and increase efficiency.


  • A Systematic Review of Minimally Invasive Procedures for Mesial Temporal Lobe Epilepsy: Too Minimal, Too Fast?

    by Ryan Wang, Usman Beg, Varun Padmanaban, Taylor J Abel, Nir Lipsman, George M Ibrahim, Alireza Mansouri

    BACKGROUND: Cortico-amygdalohippocampectomy (CAH) is effective for mesial temporal lobe epilepsy (mTLE). Concerns regarding surgical morbidity have generated enthusiasm for more minimally invasive interventions. A careful analysis of current data is warranted before widespread adoption of these techniques. OBJECTIVE: To systematically review the use of laser interstitial thermal therapy (LITT), stereotactic radiosurgery (SRS), radiofrequency thermocoagulation (RF-TC), and focused ultrasound for mTLE. METHODS: Major online databases were searched for prospective observational studies, randomized clinical trials, and retrospective studies (>50 patients), including mTLE patients. Outcomes of interest were seizure freedom (Engel I), complications and re-operation rates, and neuropsychological and quality-of-life (QoL) data. RESULTS: Nineteen publications were identified. At ≥6 mo postoperatively, LITT (9/19) Engel I outcomes ranged from 52% to 80%. SRS (3/19) has a latency period (52%-67%, 24-36 mo postoperatively) and the radiosurgery vs. open surgery for epilepsy (ROSE) trial reported inferiority of SRS compared to CAH. RF-TC (7/19) demonstrated variable seizure freedom rates (0%-79%) and high re-operation rates (0%-90%). Twelve studies reported neuropsychological outcomes but QoL (4/19) was not widely reported, and few studies (3/19) assessed both. Study quality ranged from fair to good. CONCLUSION: Based on nonrandomized data, LITT has compelling evidence of efficacy; however, comparisons to surgical resection are lacking. SRS has a latency period and is inferior to CAH (ROSE trial). RF-TC is a less resource-intensive alternative to LITT; however, comparisons of efficacy are limited. Additional studies are needed before minimally invasive procedures can supplant standard surgery.


  • Reduction in Stroke After Transient Ischemic Attack in a Province-Wide Cohort Between 2003 and 2015

    by Ryan Wang, Arunima Kapoor, Patrice Lindsay, Cristina Goia, Amy Y. X. Yu, David J. Gladstone, Richard H. Swartz

    Background: Improvements in management of transient ischemic attack (TIA) have decreased stroke and mortality post-TIA. Studies examining trends over time on a provincial level are limited. We analyzed whether efforts to improve management have decreased the rate of stroke and mortality after TIA from 2003 to 2015 across an entire province. Methods: Using administrative data from the Canadian Institute for Health Information’s (CIHI) databases from 2003 to 2015, we identified a cohort of patients with a diagnosis of TIA upon discharge from the emergency department (ED). We examined stroke rates at Day 1, 2, 7, 30, 90, 180, and 365 post-TIA and 1-year mortality rates and compared trends over time between 2003 and 2015. Results: From 2003 to 2015 in Ontario, there were 61,710 patients with an ED diagnosis of TIA. Linear regressions of stroke after the index TIA showed a significant decline between 2003 and 2015, decreasing by 25% at Day 180 and 32% at 1 year (p < 0.01). The 1-year stroke rate decreased from 6.0% in 2003 to 3.4% in 2015. Early (within 48 h) stroke after TIA continued to represent approximately half of the 1-year event rates. The 1-year mortality rate after ED discharge following a TIA decreased from 1.3% in 2003 to 0.3% in 2015 (p < 0.001). Interpretation: At a province-wide level, 1-year rates of stroke and mortality after TIA have declined significantly between 2003 and 2015, suggesting that efforts to improve management may have contributed toward the decline in long-term risk of stroke and mortality. Continued efforts are needed to further reduce the immediate risk of stroke following a TIA. RÉSUMÉ : Réduction du nombre d’AVC consécutifs à des accidents ischémiques transitoires au sein d’une cohorte de patients d’une même province canadienne. Contexte : Les améliorations dans la prise en charge des accidents ischémiques transitoires (AIT) ont eu pour effet de réduire le nombre d’AVC et le taux de mortalité post AIT. Chose certaine, les études examinant ces tendances au niveau des provinces et dans le temps sont rares. Nous avons ainsi analysé dans quelle mesure les efforts pour améliorer la prise en charge des patients ont permis de diminuer leur taux d’AVC et leur taux de mortalité à la suite d’un AIT, et ce, de 2003 à 2015 en Ontario. Méthodes : C’est au moyen de données administratives de l’Institut canadien d’information sur la santé (ICIS) que nous avons identifié une cohorte de patients chez qui l’on avait diagnostiqué un AIT avant qu’ils n’obtiennent leur congé d’un service d’urgence. Nous avons alors examiné leurs taux d’AVC pour les jours 1, 2, 7, 30, 90, 180 et 365 consécutifs à un AIT ainsi que leurs taux de mortalité au bout de 12 mois pour ensuite analyser l’évolution des tendances entre 2003 et 2015. Résultats : En Ontario, de 2003 à 2015, on a recensé 61 710 patients chez qui l’on avait diagnostiqué un AIT après une admission dans un service d’urgence. Des régressions linéaires des AVC après un AIT initial ont montré une réduction notable de leur nombre entre 2003 et 2015, à savoir 25 % au jour 180 et 32 % au bout de 12 mois (p < 0,01). Le taux d’AVC au bout de 12 mois est également passé de 6,0 % en 2003 à 3,4 % en 2015. Des AVC apparus rapidement à la suite d’un AIT, c’est-à-dire dans les 48 heures, ont continué à représenter environ la moitié des incidents survenus pendant 12 mois. Enfin, le taux de mortalité de ces patients 12 mois après leur congé d’un service d’urgence est passé de 1,3 % en 2003 à 0,3 % en 2015 (p < 0,001). Interprétation : À l’échelle de l’Ontario, on observe donc que les taux d’AVC ainsi que les taux de mortalité pendant une période de 12 mois ont été réduits de manière notable entre 2003 et 2015, ce qui suggère que les efforts pour améliorer la prise en charge des patients pourraient avoir contribué à la réduction des risques à long terme d’être victime d’un AVC et d’en décéder. Il s’ensuit que des efforts continus sont nécessaires pour réduire encore davantage les risques immédiats d’AVC à la suite d'un AIT.


  • Novel molecular therapeutic targets in cardiac fibrosis: a brief overview

    by Ryan Wang, Justin Lin, Rushita A. Bagchi

    Cardiac fibrosis, characterized by excessive accumulation of extracellular matrix, abolishes cardiac contractility, impairs cardiac function, and ultimately leads to heart failure. In recent years, significant evidence has emerged that supports the highly dynamic and responsive nature of the cardiac extracellular matrix. Although our knowledge of cardiac fibrosis has advanced tremendously over the past decade, there is still a lack of specific therapies owing to an incomplete understanding of the disease etiology and process. In this review, we attempt to highlight some of the recently investigated molecular determinants of ischemic and non-ischemic fibrotic remodeling of the myocardium that present as promising avenues for development of anti-fibrotic therapies.


  • Regulation of fibronectin gene expression in cardiac fibroblasts by scleraxis

    by Rushita A. Bagchi, Justin Lin, Ryan Wang, Michael P. Czubryt

    The glycoprotein fibronectin is a key component of the extracellular matrix. By interacting with numerous matrix and cell surface proteins, fibronectin plays important roles in cell adhesion, migration and intracellular signaling. Up-regulation of fibronectin occurs in tissue fibrosis, and previous studies have identified the pro-fibrotic factor TGFβ as an inducer of fibronectin expression, although the mechanism responsible remains unknown. We have previously shown that a key downstream effector of TGFβ signaling in cardiac fibroblasts is the transcription factor scleraxis, which in turn regulates the expression of a wide variety of extracellular matrix genes. We noted that fibronectin expression tracked closely with scleraxis expression, but it was unclear whether scleraxis directly regulated the fibronectin gene. Here, we report that scleraxis acts via two E-box binding sites in the proximal human fibronectin promoter to govern fibronectin expression, with the second E-box being both sufficient and necessary for scleraxis-mediated fibronectin expression to occur. A combination of electrophoretic mobility shift and chromatin immunoprecipitation assays indicated that scleraxis interacted to a greater degree with the second E-box. Over-expression or knockdown of scleraxis resulted in increased or decreased fibronectin expression, respectively, and scleraxis null mice presented with dramatically decreased immunolabeling for fibronectin in cardiac tissue sections compared to wild-type controls. Furthermore, scleraxis was required for TGFβ-induced fibronectin expression: TGFβ lost its ability to induce fibronectin expression following scleraxis knockdown. Together, these results demonstrate a novel and required role for scleraxis in the regulation of cardiac fibroblast fibronectin gene expression basally or in response to TGFβ.


  • Regulation of scleraxis transcriptional activity by serine phosphorylation

    by Rushita A. Bagchi, Ryan Wang, Fahmida Jahan, Jeffrey T. Wigle, Michael P. Czubryt